# COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

> **NCT03917459** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Heart Failure
- Heart Failure, Systolic
- Erectile Dysfunction

## Interventions

- **DRUG:** LCZ696
- **DRUG:** Enalapril matching placebo
- **DRUG:** Enalapril
- **DRUG:** LCZ696 matching placebo

## Key facts

- **NCT ID:** NCT03917459
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-05-25
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03917459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03917459, "COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03917459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*